+++  Auf die Schnelle, ihr könnt ja Englisch: Study says MS drugs from Biogen, Bayer too expensive in US. Biogen Idec Inc. and Bayer AG would have to cut the price of their multiple sclerosis drugs by at least two-thirds in the United States to make them cost effective at boosting quality of life, a study found; via Boston Globe.
Dazu auch: Neurology, New York Times, Bloomberg, Reuters